Analysts Set IQVIA Holdings Inc. (NYSE:IQV) PT at $225.69

Shares of IQVIA Holdings Inc. (NYSE:IQV) have received an average rating of “Buy” from the seventeen brokerages that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $225.6875.

IQV has been the topic of a number of research analyst reports. Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price on the stock in a research report on Friday, March 6th. JPMorgan Chase & Co. decreased their price objective on IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research report on Friday, February 6th. Mizuho set a $215.00 price objective on IQVIA in a research report on Monday, February 23rd. Morgan Stanley set a $225.00 price objective on IQVIA in a research report on Thursday, May 7th. Finally, Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research report on Sunday, April 19th.

IQVIA Price Performance

NYSE:IQV opened at $168.28 on Friday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The company has a market capitalization of $28.09 billion, a P/E ratio of 20.85, a P/E/G ratio of 1.61 and a beta of 1.18. IQVIA has a 12 month low of $134.65 and a 12 month high of $247.04. The business’s 50-day moving average is $169.72 and its 200 day moving average is $197.56.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The company had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same period in the previous year, the business earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities research analysts forecast that IQVIA will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has initiated a share repurchase plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board of directors believes its stock is undervalued.

Institutional Investors Weigh In On IQVIA

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Ameliora Wealth Management Ltd. bought a new position in shares of IQVIA during the fourth quarter valued at approximately $25,000. Financial Freedom LLC bought a new position in shares of IQVIA during the first quarter valued at approximately $25,000. Ascentis Independent Advisors bought a new position in shares of IQVIA during the first quarter valued at approximately $25,000. Physician Wealth Advisors Inc. grew its stake in shares of IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after buying an additional 134 shares during the last quarter. Finally, International Assets Investment Management LLC bought a new position in shares of IQVIA during the fourth quarter valued at approximately $27,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.